Koshinski Asset Management
RGNX icon

Koshinski Asset Management’s Regenxbio RGNX Stock Holding History

Koshinski Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-600
Closed -$19.9K – 1674
2022
Q1 		$19.9K Hold
600
– – ﹤0.01% 1416
2021
Q4 		$19.6K Hold
600
– – ﹤0.01% 1453
2021
Q3 		$25.2K Buy
+600
New +$21.6K ﹤0.01% 1369

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Koshinski Asset Management's RGNX Position: Q2 2022 in Review

Koshinski Asset Management sold out of Regenxbio (RGNX) in Q2 2022, closing a stake of 600 shares — an estimated $19.9K sold.

Koshinski Asset Management first reported a position in RGNX in Q3 2021 and held it in 3 quarters. The position peaked at $25.2K in Q3 2021. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2022.

  • Koshinski Asset Management reported no remaining Regenxbio position as of Q2 2022 after selling out during the quarter.
  • Koshinski Asset Management sold 600 Regenxbio shares in Q2 2022, an estimated $19.9K.
  • Koshinski Asset Management first reported a position in Regenxbio in Q3 2021 and held it in 3 quarters.
  • Koshinski Asset Management's Regenxbio position peaked at $25.2K in Q3 2021.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2022.

Based on Koshinski Asset Management's 13F filing for Q2 2022, filed 12 Jul 2022.